umbilical cord blood stem cell-derived therapy (Kang Stem Biotech/Heraeus Medical)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameumbilical cord blood stem cell-derived therapy (Kang Stem Biotech/Heraeus Medical)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Umbilical cord stem cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsOsteoarthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKangstem Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKangstem Biotech Co LtdHeraeus Medical Gmbh
Active IndicationsN/A
Inactive IndicationsOsteoarthritis

Other Information

ATC CodeN/A
Related LinksN/A